Introduction
============

Interleukin-1β (IL-1β) plays a key role in the pathogenesis of systemic juvenile idiopathic arthritis (SJIA). Efficacy and safety of canakinumab (CAN), a selective, fully human, anti- IL-1β monoclonal antibody, have been demonstrated in 2 phase III trials. Here we present 12-week results of a post-hoc pooled analysis.

Objectives
==========

To evaluate the 12-week efficacy of CAN 4 mg/kg in treatment naïve patients (pts).

Methods
=======

Data from the 3 trials done as part of the phase III program were pooled for this analysis. Pts aged 2-19 yrs with active SJIA were enrolled and received subcutaneous CAN 4 mg/kg or placebo. The post-hoc analysis presented here focuses on SJIA response to CAN therapy in the initial treatment period of a total of 178 CAN-naïve pts. Methodological factors precluded a comparator group, so this analysis is of a descriptive nature.

Results
=======

At baseline (BL), 94% of pts had intermittent spiking fever due to SJIA; and 73% were on steroids (mean dose of 0.38 mg/kg/d). In the pooled analysis (N = 178), by Week 2 evidence of profound clinical benefit was observed (Table [1](#T1){ref-type="table"}) with 20% of pts even achieving inactive disease.

###### 

Percentage of patients with adapted JIA ACR (aacr) response and inactive disease

  CAN, N = 178                                                                     
  -------------- ------------ ------------ ------------ ------------ ------------- ----------------------
  **N(%)**       **Aacr30**   **Aacr50**   **Aacr70**   **Aacr90**   **Aacr100**   **Inactive disease**
                                                                                   
  **Week 2**     142 (80%)    125 (70%)    102 (57%)    65 (37%)     38 (21%)      36 (20%)
                                                                                   
  **Week 12**    125 (70%)    122 (69%)    108 (61%)    87 (49%)     54 (30%)      50 (28%)

Data from missing patients not shown; aacr response = ACR response level plus absence of fever

The median CRP level of 158 mg/L at BL decreased by a median of 82% and 94% by weeks 2 and 12, respectively. Rapid improvements were also observed in the number of active joints. The median number of active joints decreased from 10 at BL to 2.5 at Week 2 and 0 at Week 12. Similarly, for joints with limitation of motion, median values decreased from 9 at BL to 2.5 and 1 at Week 2 and 12, respectively. While 94% pts had fever due to SJIA at BL, only 13% at Week 2 and 2% at Week 12 had fever. Notably, CAN therapy resulted in marked improvement in patient reported outcomes: parent/patient assessment of pain (0-100 mm, VAS) decreased from a mean of 67 mm at BL to 22 mm at Week 2 and 11 mm at Week 12. The median CHAQ disability score decreased from 1.8 at BL to 0.6 at Week 2 and 0.3 at Week 12. Between BL and Week 12, the median physicians\' global assessment of SJIA activity (0-100 mm, VAS) decreased from 70 mm to 3 mm and the parents\'/patients\' assessment of overall well-being improved from 63 mm to 4.5 mm.

Conclusion
==========

Based on this post-hoc analysis, response of the SJIA patients studied for the phase III program of CAN showed a rapid and clinically important improvement of their disease by Week 12 of therapy, with an aacr 50 or higher responses reached by the majority of the CAN-naïve pts within 2 weeks after the initial CAN dose.
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